Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the introduction of irinotecan (Pharmacia's Camptosar, Aventis and Yakult's Campto) in the United States and Europe, will dramatically increase sales in the small-cell lung cancer (SCLC) therapy market.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"Irinotecan is poised to make a significant contribution to the small-cell lung cancer market. The compound will increasingly replace etoposide and it has the potential to double sales of cytotoxics during our 2001-2011 forecast period," said Mohamed Muhsin, analyst at Decision Resources.

According to the new Pharmacor study entitled Small-Cell Lung Cancer, another factor that will add to the growth of the market will be the launch of a premium-priced immunotherapy such as ImClone/Merck KgaA's mitumomab, a monoclonal antibody, and SR Pharma's SRL-172, a vaccine. Both therapies are candidates to become the first-to-market SCLC immunotherapy by 2007.

Disease Background-Small-Cell Lung Cancer

Lung cancer is the most frequently diagnosed form of cancer in men in the United States and Europe and the leading cause of cancer mortality in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Small-cell lung cancer (SCLC) is the most aggressive lung cancer: a minority of patients lives more than one year after diagnosis and the five-year survival rate is less than 10%.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Small-Cell Lung Cancer is an Onkos study.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

New Report Finds that Total HMO Enrollment Decreases in Metropolitan Statistical Areas

View Now